scholarly journals Polyglandular Dysfunction in Patients With Type 1 Diabetes: Recurrent Hypoglycemia Is an Alarming Symptom: TABLE 1.

2016 ◽  
Vol 34 (2) ◽  
pp. 113-114
Author(s):  
Aasem Saif
Keyword(s):  
Type 1 Diabetes ◽  
Recurrent Hypoglycemia ◽  
Alarming Symptom

scholarly journals Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes

Diabetes ◽  
2016 ◽  
Vol 65 (10) ◽  
pp. 3151-3160 ◽  
Author(s):  
Alison D. McNeilly ◽  
Jennifer R. Gallagher ◽  
Albena T. Dinkova-Kostova ◽  
John D. Hayes ◽  
John Sharkey ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cognitive Impairment ◽  
Rodent Model ◽  
Recurrent Hypoglycemia

370-P: Changes in Glutamate Dynamics in the Anterior Cingulate Cortex with Recurrent Hypoglycemia in Type 1 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 370-P
Author(s):  
YOUNG WOO PARK ◽  
DINESH DEELCHAND ◽  
ANJALI KUMAR ◽  
AMIR MOHEET ◽  
YUAN ZHANG ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Anterior Cingulate Cortex ◽  
Cingulate Cortex ◽  
Anterior Cingulate ◽  
Recurrent Hypoglycemia

scholarly journals Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

2017 ◽  
Vol 13 (02) ◽  
pp. 75 ◽  
Author(s):  
Gagan Priya ◽  
Sanjay Kalra ◽  
Vishal Bhambri ◽  
◽  
◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Diabetic Ketoacidosis ◽  
Insulin Dose ◽  
Unmet Need ◽  
Sglt2 Inhibitors ◽  
Dose Requirement ◽  
Dual Inhibitors ◽  
Recurrent Hypoglycemia

There is an unmet need for adjunctive non-insulin-based therapies in type 1 diabetes (T1D). Weight gain, recurrent hypoglycemia and suboptimal glycemic control remain significant challenges. Sodium-glucose co-transporter-2 (SGLT2) inhibitors and dual inhibitors of sodium-glucose co-transporter-1 (SGLT1) and SGLT2 may have a potential role as an add-on therapy to insulin. The benefits include improved glycemic control, weight reduction, and reduced insulin dose requirement. However, the risk of diabetic ketoacidosis with SGLT2 inhibitors is significant and the diagnosis may be delayed due to absence of significant hyperglycemia. At present, SGLT2 inhibitors are not approved for use in T1D, and the risks should be discussed at length with the patient. We propose strategies to minimize the risk of diabetic ketoacidosis associated with off-label use of SGLT2 inhibitors in T1D.

scholarly journals Beyond the barriers of the use of continuous subcutaneous insulin therapy in type 1 diabetes: a new opportunity from catheter-less insulin pumps

ABOUTOPEN ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 55-70
Author(s):  
Katherine Esposito ◽  
Andrea Mario Bolla ◽  
Francesco Costantino ◽  
Maurizio Delvecchio ◽  
Chiara Molinari ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Infusion ◽  
Insulin Pump ◽  
Drop Out ◽  
Insulin Pump Therapy ◽  
Subcutaneous Insulin ◽  
Insulin Pumps ◽  
Pump Therapy ◽  
Recurrent Hypoglycemia

Although it represents a valid alternative for patients with type 1 diabetes (T1DM) with insufficient glycemic control and/or with recurrent hypoglycemia, insulin pump therapy (Continuous Subcutaneous Insulin Infusion, CSII) in Italy is nowadays still relatively uncommon. The following review aims to investigate the barriers that limit the transition to CSII and the reasons behind the widespread cases of drop-out, particularly evident in younger patients. Among the interventions that could contribute to the solution of the problem, catheter-less insulin pumps (or patch-pumps) will be described: a tool potentially able to reduce, if not eliminate, some of the main obstacles encountered by patients. In particular, a new opportunity has become available today thanks to the evolution of the generation of catheter-less insulin pumps represented by Accu-Chek® Solo (Roche Diabetes Care GmbH), therefore three clinical cases of patients with T1DM undergoing therapy with the Accu-Chek® Solo insulin pump will be presented and discussed herein.

scholarly journals Metabolic control in patients with type 1 diabetes mellitus at the onset of primary adrenal insufficiency

2013 ◽  
Vol 10 (2) ◽  
pp. 38-41
Author(s):  
A A Larina ◽  
E A Troshina
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Adrenal Insufficiency ◽  
Insulin Requirement ◽  
Primary Adrenal Insufficiency ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid ◽  
Recurrent Hypoglycemia

Primary adrenal insufficiency is a rare disorder but it is more common in patients with type 1 diabetes mellitus (T1DM) or autoimmune thyroid diseases than in the general population. T1DM may precede the development of adrenocortical insufficiency. Addison’s disease can influence the glycemic control in patients with T1DM worsening glucose metabolism. It causes the decrease of gluconeogenesis, reduction in total insulin requirement and rather often «unexplained» recurrent hypoglycemia. Glucocorticoid replacement therapy in patients with primary adrenal insufficiency and T1DM increases the insulin requirement. The article presents the development of primary adrenal insufficiency in a patient with type 1 DM and autoimmune hypothyroidism, accompanied with incidents of recurrent hypoglycemia.

Sign in / Sign up

Export Citation Format

Share Document